Morgan Stanley downgraded R1 RCM from Overweight to Equal-Weight
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 8/8/2024 | Overweight → Equal-Weight | Morgan Stanley | |
| 8/1/2024 | Overweight → Equal-Weight | Stephens | |
| 8/1/2024 | Outperform → Market Perform | Leerink Partners | |
| 8/1/2024 | Buy → Hold | Jefferies | |
| 4/10/2024 | Overweight → Sector Weight | KeyBanc Capital Markets | |
| 3/20/2024 | $16.00 | Neutral → Buy | Citigroup |
| 2/26/2024 | $14.00 | Outperform | Leerink Partners |
| 1/3/2024 | $14.00 | Overweight | Barclays |
Morgan Stanley downgraded R1 RCM from Overweight to Equal-Weight
Stephens downgraded R1 RCM from Overweight to Equal-Weight
Leerink Partners downgraded R1 RCM from Outperform to Market Perform
SC 13D/A - R1 RCM Inc. /DE (0001910851) (Subject)
SC 13D/A - R1 RCM Inc. /DE (0001910851) (Subject)
SC 13D/A - R1 RCM Inc. /DE (0001910851) (Subject)
DEFA14A - R1 RCM Inc. /DE (0001910851) (Filer)
8-K - R1 RCM Inc. /DE (0001910851) (Filer)
SC 13E3/A - R1 RCM Inc. /DE (0001910851) (Subject)
MURRAY, Utah, Aug. 07, 2024 (GLOBE NEWSWIRE) -- R1 RCM Inc. (NASDAQ:RCM) ("R1" or the "Company"), a leading provider of technology-driven solutions that transform the patient experience and financial performance of healthcare providers, today announced results for the three months ended June 30, 2024. Second Quarter 2024 Results: Revenue of $627.9 million, up $67.2 million or 12.0% compared to the same period last year.GAAP net loss of $7.6 million, compared to net loss of $1.0 million in the same period last year.Adjusted EBITDA of $156.1 million, compared to adjusted EBITDA of $142.9 million in the same period last year. The quarte
MURRAY, Utah, Aug. 01, 2024 (GLOBE NEWSWIRE) -- R1 RCM Inc. (NASDAQ:RCM) ("R1" or the "Company"), a leading provider of technology-driven solutions that transform the patient experience and financial performance of healthcare providers, today announced that it has entered into a definitive agreement to be acquired by investment funds affiliated with TowerBrook Capital Partners and Clayton, Dubilier & Rice ("CD&R"), in an all-cash transaction with an enterprise value of approximately $8.9 billion. An investment vehicle controlled by TowerBrook is currently the beneficial owner of approximately 36% of the Company's outstanding shares of common stock, including the warrant held by TowerBrook.
MURRAY, Utah, July 24, 2024 (GLOBE NEWSWIRE) -- The Special Committee of the R1 RCM Inc. (NASDAQ:RCM) ("R1" or the "Company") Board of Directors, which comprises independent directors and was formed to evaluate strategic alternatives in response to the Schedule 13D/A filed by New Mountain Capital, L.L.C. ("New Mountain Capital") with the Securities and Exchange Commission on February 26, 2024, today announced it has set a final deadline for interested parties to submit fully-financed bids on July 31, 2024 in connection with its review process. No assurances can be given regarding the outcome or timing of the Special Committee's review process. The Special Committee continues to evaluate a
4 - R1 RCM Inc. /DE (0001910851) (Issuer)
4 - R1 RCM Inc. /DE (0001910851) (Issuer)
4 - R1 RCM Inc. /DE (0001910851) (Issuer)
8 analysts have shared their evaluations of R1 RCM (NASDAQ:RCM) during the recent three months, expressing a mix of bullish and bearish perspectives. In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 2 5 1 0 0 Last 30D 1 0 0 0 0 1M Ago 0 4 1 0 0 2M Ago 0 1 0 0 0 3M Ago 1 0 0 0 0 In the assessment of 12-month price targets, analysts unveil insights for R1 RCM, presenting an average target of $17.38, a high estimate of $20.00, and a low estimate of $15.00. Observing a 0.75% increase, t
Canaccord Genuity analyst Richard Close maintains R1 RCM (NASDAQ:RCM) with a Buy and maintains $15 price target.
Rachel Wilson appointed as Chief Financial Officer (CFO) James Hardie Industries plc ((ASX: JHX, NYSE:JHX), the world's #1 producer and marketer of high-performance fiber cement and fiber gypsum building solutions, today announced the appointment of Ms. Rachel Wilson as Chief Financial Officer, effective immediately. As a member of the global executive team, Ms. Wilson will report directly to Chief Executive Officer Aaron Erter. Ms. Wilson was appointed after Jason Miele stepped down as Chief Financial Officer. Mr. Miele will remain with the Company for three months as an advisor to the Chief Executive Officer for special projects and will thereafter depart the organization. "I would li
MURRAY, Utah, Aug. 12, 2021 (GLOBE NEWSWIRE) -- R1 RCM Inc. (NASDAQ:RCM), a leading provider of technology-driven solutions that transform the patient experience and financial performance of healthcare providers, today announced the appointment of Agnes Bundy Scanlan, president of The Cambridge Group LLC, to the company's board of directors, effective August 11, 2021. Ms. Bundy Scanlan has more than 30 years of experience across regulatory risk management, compliance, and consumer financial protection. She has served as president of The Cambridge Group LLC, a regulatory risk management advisory firm, since May 2020. Prior to this role, Ms. Bundy Scanlan served as senior advisor at Trelian
MURRAY, Utah, Aug. 02, 2021 (GLOBE NEWSWIRE) -- R1 RCM Inc. (NASDAQ:RCM), a leading provider of technology-driven solutions that transform the patient experience and financial performance of healthcare providers, today announced that Jay Sreedharan will join the executive team as its first chief technology and digital officer. Sreedharan will lead R1's efforts in creating digital solutions that drive higher-value experiences for patients and providers. In this role, Sreedharan will be responsible for delivering on R1's promise of digital transformation and growth, including strategy, engineering, product development, architecture and implementation, as well as future digital M&A and partn
MURRAY, Utah, Aug. 07, 2024 (GLOBE NEWSWIRE) -- R1 RCM Inc. (NASDAQ:RCM) ("R1" or the "Company"), a leading provider of technology-driven solutions that transform the patient experience and financial performance of healthcare providers, today announced results for the three months ended June 30, 2024. Second Quarter 2024 Results: Revenue of $627.9 million, up $67.2 million or 12.0% compared to the same period last year.GAAP net loss of $7.6 million, compared to net loss of $1.0 million in the same period last year.Adjusted EBITDA of $156.1 million, compared to adjusted EBITDA of $142.9 million in the same period last year. The quarte
MURRAY, Utah, Aug. 01, 2024 (GLOBE NEWSWIRE) -- R1 RCM Inc. (NASDAQ:RCM) ("R1" or the "Company"), a leading provider of technology-driven solutions that transform the patient experience and financial performance of healthcare providers, today announced that it has entered into a definitive agreement to be acquired by investment funds affiliated with TowerBrook Capital Partners and Clayton, Dubilier & Rice ("CD&R"), in an all-cash transaction with an enterprise value of approximately $8.9 billion. An investment vehicle controlled by TowerBrook is currently the beneficial owner of approximately 36% of the Company's outstanding shares of common stock, including the warrant held by TowerBrook.
MURRAY, Utah, July 15, 2024 (GLOBE NEWSWIRE) -- R1 RCM Inc. (NASDAQ:RCM), a leading provider of technology-driven solutions that transform the patient experience and financial performance of healthcare providers, today announced it expects to release financial results for the three months ended June 30, 2024, before market open on Wednesday, August 7, 2024 and host a conference call at 8:00 a.m. ET to review the results. Investors and other interested parties are invited to listen to the conference call by dialing 888-596-4144 (646-968-2525 outside the U.S. and Canada) using conference code number 9123341. A live webcast and replay of the call will be available at the Investor Relations s